Soffinova News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Back pain device group Mainstay Medical raises $108m
Funding will drive commercialisation of Reactiv8 in critical US market
Tue, Feb 16, 2021, 13:00
Updated: Tue, Feb 16, 2021, 18:24
Irish company Mainstay Medical has developed a device to address chronic lower back pain
Your Web Browser may be out of date. If you are using Internet Explorer 9, 10 or 11 our Audio player will not work properly.
 
Irish company Mainstay Medical, which has developed a device to address chronic lower back pain, has raised $108 million(€89 million) to commercialise it in the US market.
Mainstay, which is based in Dublin, secured approval from the US regulator – the Food and Drug Administration – in June to sell it Reactiv8 device in the US, the world’s largest medical device market, to adult patients with chronic lower back pain who have failed to experience relief with other therapies and are not candidates for spine surgery. ....

France General , Drug Administration , Pharma Medtech , Jason Hannon , Manus Rogan , Food And Drug Administration , Rally Bridge , Fountain Healthcare , Kck Group , Mainstay Medical , Wuxi Biologics , Dublin Ie , Paris Fr , United States , Reactiv8 Device , Chronic Lower Back Pain , பிரான்ஸ் ஜநரல் , பார்மா மெதிதேச் , ஜேசன் ஹன்னன் , மனுச் ரோகன் , நட்பு பாலம் , நீரூற்று சுகாதாரம் , கக்க் குழு , பிரதான மருத்துவ , டப்ளின் அதாவது , பாரிஸ் ஃப்ர் ,